• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    The Journal of rheumatology

    The Journal of rheumatology

    JournalISSN 0315-162XeISSN 1499-2752中科院 医学 3区

    年发文量

    研究主题

    论文(63160)

    排序
    1Selection Collider Bias in Rheumatology
    Richard J. Cook,Jerald F. Lawless,Lily Zou

    Conditions affecting the selection of individuals for a study are a common source of bias in epidemiological and medical research. A recent trend in epidemiology has been to link selection conditions to the concept of collider variables. The effects of selection and associated collider variables depend on the composition of the study population, the study selection process, the target of inference, and methods of data collection and analysis. We give here an introduction to bias arising from selection effects, termed selection collider bias, and discuss ways of avoiding it. We provide illustrations related to two apparent paradoxes in rheumatology that involve smoking. The first paradox is that smoking, a risk factor for rheumatoid arthritis (RA), appears to be protective for disease progression in RA. The second is that smoking is a risk factor for psoriatic arthritis (PsA), but in some studies involving persons with psoriasis it appears to reduce the risk of PsA. Using data from the Gladman-Krembil Psoriatic Arthritis Research Program we examine the effect of smoking on the development of PsA in individuals with psoriasis and resolve the paradox. collider variables, confounding, directed acyclic graphs, observational data, selection effects.

    2026
    引用
    AI阅读
    加入学术空间
    2Redefining BASDAI Cut-Offs in Axial Spondyloarthritis: Implications for Patients' Eligibility for Treatment with Biologic Disease-Modifying Antirheumatic Drugs
    Stylianos Georgiadis,Lykke Midtbøll Ørnbjerg,Brigitte Michelsen,Tore K. Kvien,Mehrdad Shoae Kazemi,Kristýna Bubová,Heřman Mann,Karel Pavelka,Bente Glintborg,Anne Gitte Loft,Helena Santos, Andreas Reich,

    Objective To compare a newly proposed Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) cut-off for high disease activity (BASDAI≥2.5) with the corresponding Axial Spondyloarthritis Disease Activity Score (ASDAS) cut-off (ASDAS≥2.1) as an eligibility criterion for initiating a biologic disease-modifying antirheumatic drug (bDMARD) in routine care patients with axial spondyloarthritis (axSpA). Methods Real-world patients with axSpA initiating their first bDMARD from 9 European registries were analysed. Patients were categorised into 4 subgroups according to the fulfilment of ASDAS and BASDAI criteria at baseline, and treatment effect was assessed at 6 months using several response and remission outcomes. Adjusted logistic regression analyses were performed to determine whether fulfilling ASDAS and BASDAI criteria was associated with achieving the treatment outcomes. Results Of 6,329 patients included, 90.9% fulfilled both ASDAS and BASDAI eligibility criteria at baseline, 2.5% and 2.7% fulfilled either ASDAS or BASDAI criterion alone, while 3.8% fulfilled neither. The subgroup fulfilling both criteria demonstrated the highest responses at 6 months, while the highest remission outcomes were observed in the subgroup fulfilling neither criterion. Fulfilling either criterion at baseline was significantly associated with achieving response outcomes at 6 months, whereas a negative association was observed for remission outcomes. Conclusion In a multinational European cohort, a very large overlap between the BASDAI and the ASDAS eligibility criteria was shown, and the predictive ability of the two criteria to achieve treatment outcomes was comparable. These findings support the use of BASDAI≥2.5 as a criterion for initiating bDMARD therapy in axSpA, particularly when ASDAS is unavailable.

    2026
    引用
    AI阅读
    加入学术空间
    3Rethinking Rheumatoid Arthritis Performance Measures in the Context of Meaningful Clinical Outcomes
    Sharika G. Menon, Beverly K. Johnson
    2026
    引用
    AI阅读
    加入学术空间
    4Not Just Another Calcinosis Clinical Case
    Bianca Paulo Correia,Ana Teresa Melo, Oana Moldovan,Raquel Campanilho-Marques

    Calcinosis affects 20% to 40% of patients with juvenile dermatomyositis (JDM), and is associated in particular with antinuclear matrix protein 2 (anti-NXP2) antibodies, younger age at disease onset, and persistent disease activity.1-3 Extensive calcinosis beginning in early childhood is rare. No treatment is uniformly effective, although Janus kinase ( JAK) inhibitors have emerged as an option for refractory calcinosis.2,4

    2026
    引用
    AI阅读
    加入学术空间
    5An Unusual Presentation of Erythropoietin-Induced Acute Monoarthritis in a Patient with Myelodysplastic Syndrome and Behçet Disease: A Case Report
    Ilham Ouamer, Samia Belkhadir, Moulay Jihad Berkchi, Lahsen Achemlal

    Erythropoiesis (EPO)-stimulating agents (ESAs) are recommended first-line therapy for symptomatic anemia in lower-risk myelodysplastic syndrome (MDS), reducing transfusion dependence in 40% to 60% of eligible patients.1 Arthralgia and myalgia are recognized side effects of ESAs,1 but evident inflammatory monoarthritis directly attributable to ESA therapy has not, to our knowledge, been previously reported.

    2026
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 63160 篇论文

    高被引作者

    作者引用发文
    Dafna Gladman37438933
    G. J. Huston353482
    Murray Urowitz26572398
    Fred Wolfe19688190
    Désirée Van Der Heijde19055539
    Jasvinder Singh17336231
    Nicholas Bellamy1550746
    Peter Tugwell14217248
    Dinesh Khanna13967326
    A Calin1345452

    高产作者

    作者引用发文
    Dafna Gladman37438933
    Janet Pope8687611
    Philip J. Mease12822607
    Désirée Van Der Heijde19055539
    Jeffrey Curtis5034486
    Michelle Petri10793440
    Sasha Bernatsky4642425
    W Maksymowych8860411
    Murray Urowitz26572398
    Ted R. Mikuls5263375

    相关期刊

    Rheumatic diseases clinics of North America
    Scandinavian journal of rheumatology
    Best Practice & Research Clinical Rheumatology
    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases
    RMD open
    Rheumatology advances in practice
    BMC rheumatology
    ACR open rheumatology
    Seminars in Arthritis and Rheumatism
    Advances in Rheumatology